Enabling novel fusion detection for lung cancer management

SOPHiA DDM™ Dx RNAtarget Oncology Solution (ROS), now CE-IVD and delivers a streamlined workflow from sample to report for a reduced time-to-patient benefit.

Get actionable insight into your lung cancer patient’s management with our SOPHiA DDM™ RNAtarget Technology detecting not only known but also novel fusions in newly emerging biomarkers.